|
1
|
Avagimyan A, Sheibani M, Pogosova N, Mkrtchyan L, Yeranosyan H, Aznauryan A, Sahaakyan K, Fogacci F, Cicero A, Shafie D, Sarrafzadegan N. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol 2023; 391:131331. [PMID: 37666280 DOI: 10.1016/j.ijcard.2023.131331] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 07/29/2023] [Accepted: 09/01/2023] [Indexed: 09/06/2023]
Abstract
RATIONALE The global burden of cardiovascular (CV) and oncological diseases continues to increase. In this regard, the prevention of CV diseases (CVD) before and after cancer treatment is an urgent and unsolved problem in medicine. For this reason, our research group aimed to investigate the possibility of dapagliflozin-related cardioprotection, using an experimental model of chronic Doxorubicin (Adriamycin) + Cyclophosphamide (AC)-mode of chemotherapy-induced cardiomyopathy. OBJECTIVE The redox balance, lipid metabolism, endothelial dysfunction, and myocardial damage parameters were measured to evaluate the pathways of dapagliflozin-induced stabilization of CV homeostasis. METHODS For this study, 80 inbred Wistar rats were randomly assigned to four equally sized groups. A model of chronic cardiotoxicity was attained by using doxorubicin and cyclophosphamide co-administration. In the case, the markers of redox-balance, cholesterol metabolism, endothelial dysfunction, myocardial alteration, and morphological examination were assessed. RESULTS For all parameters, statistically significant deviations were obtained, emphasizing the sequel of AC-mode chemotherapy-related detergent effect on CV system (group 2). Moreover, the data obtained from dapagliflozin-treated groups (group 3) showed that this strategy provide limitation of lipid peroxidation, cholesterol metabolism and endothelial function normalization, with subsequent morphological preservation of myocardium. CONCLUSION Dapagliflozin has a broad spectrum of pleiotropic influences, namely cholesterol-lowering, anti-inflammatory, and endothelium-stabilizing properties. These properties provide a favorable environment for the prevention of chemotherapy-related cardiomyopathy.
Collapse
Affiliation(s)
- Ashot Avagimyan
- Department of Anatomical Pathology and Clinical Morphology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.
| | - Mohammad Sheibani
- Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Razi Drug Research Centre, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Nana Pogosova
- National Medical Research Centre of Cardiology named after E. Chazov, Moscow, Russia
| | - Lusine Mkrtchyan
- Department of Cardiology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
| | - Hasmik Yeranosyan
- Department of Forensic Medicine, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
| | - Anahit Aznauryan
- Department of Histology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
| | - Karmen Sahaakyan
- Head of Histology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
| | - Federica Fogacci
- Research Fellow, Atherosclerosis and Metabolic Disorders Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy
| | - Arrigo Cicero
- Hypertension and Cardiovascular Risk Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy; Cardiovascular Medicine Unit, Heart, Chest and Vascular Dept., IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Davood Shafie
- Head of Heart Failure Centre, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran
| | - Nizal Sarrafzadegan
- Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
|
2
|
Bonanni A, d’Aiello A, Pedicino D, Di Sario M, Vinci R, Ponzo M, Ciampi P, Lo Curto D, Conte C, Cribari F, Canonico F, Russo G, Montone RA, Trani C, Severino A, Crea F, Liuzzo G. Molecular Hallmarks of Ischemia with Non-Obstructive Coronary Arteries: The "INOCA versus Obstructive CCS" Challenge. J Clin Med 2022; 11:jcm11061711. [PMID: 35330036 PMCID: PMC8951436 DOI: 10.3390/jcm11061711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 03/14/2022] [Accepted: 03/16/2022] [Indexed: 11/27/2022] Open
Abstract
Up to 4 million patients with signs of myocardial ischemia have no obstructive coronary artery disease (CAD). The absence of precise guidelines for diagnosis and treatment in non-obstructive CAD encourages the scientific community to fill the gap knowledge, to provide non-invasive and less expensive diagnostic tools. The aim of our study was to explore the biological profile of Ischemia with Non-Obstructive Coronary Arteries (INOCA) patients with microvascular dysfunction compared to patients presenting with obstructive chronic coronary syndrome (ObCCS) in order to find specific hallmarks of each clinical condition. We performed a gene expression array from peripheral blood mononuclear cells (PBMCs) isolated from INOCA (n = 18) and ObCCS (n = 20) patients. Our results showed a significantly reduced gene expression of molecules involved in cell adhesion, signaling, vascular motion, and inflammation in INOCA as compared to the ObCCS group. In detail, we found lower expression of Platelet and Endothelial Cell Adhesion Molecule 1 (CD31, p < 0.0001), Intercellular Adhesion Molecule-1 (ICAM1, p = 0.0004), Tumor Necrosis Factor (TNF p = 0.0003), Transferrin Receptor (TFRC, p = 0.002), and Vascular Endothelial Growth Factor A (VEGFA, p = 0.0006) in the INOCA group compared with ObCCS. Meanwhile, we observed an increased expression of Hyaluronidase (HYAL2, p < 0.0001) in INOCA patients in comparison to ObCCS. The distinct expression of molecular biomarkers might allow an early and non-invasive differential diagnosis between ObCCS and INOCA, improving clinical management and treatment options, in the era of personalized medicine.
Collapse
Affiliation(s)
- Alice Bonanni
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Alessia d’Aiello
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Daniela Pedicino
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
- Correspondence: ; Tel.: +39-06-3015-4187
| | - Marianna Di Sario
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
| | - Ramona Vinci
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Myriana Ponzo
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
| | - Pellegrino Ciampi
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
| | - Denise Lo Curto
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
| | - Cristina Conte
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
| | - Francesco Cribari
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
| | - Francesco Canonico
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Giulio Russo
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Rocco Antonio Montone
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Carlo Trani
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Anna Severino
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Filippo Crea
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| | - Giovanna Liuzzo
- Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy; (A.B.); (A.d.); (M.D.S.); (R.V.); (M.P.); (P.C.); (D.L.C.); (C.C.); (F.C.); (G.R.); (R.A.M.); (C.T.); (A.S.); (F.C.); (G.L.)
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
| |
Collapse
|